Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole proteome characterisation following treatment with α-helix mimetic inhibitors of MDM2

ABSTRACT: A wide range of small molecule scaffolds capable of mimicking protein α-helices to modulate protein-protein interactions have been reported, yet their target selectivity is poorly understood. Here, we report the changes to the whole protoeme of SJSA-1 osteosarcoma cells following treatment with three structurally distinct classes of α-helix mimetics, N-substituted oligobenzamides, pyrrolopyrimidines, and oxopiperazines, all reported to inhibit the interaction between the tumour suppressor protein p53 and its negative regulator murine double minute 2 (MDM2).

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Amrita Date

LAB HEAD: Anna Barnard

PROVIDER: PXD063398 | Pride | 2026-08-05

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	AD_MS_049_DMSO_A_S3-F9_1_6202.d.zip	Other
	AD_MS_049_DMSO_B_S3-G2_1_6207.d.zip	Other
	AD_MS_049_DMSO_C_S3-G7_1_6212.d.zip	Other
	AD_MS_049_DMSO_D_S3-G12_1_6217.d.zip	Other
	AD_MS_049_OB-a1_A_S3-F10_1_6203.d.zip	Other

Items per page:

1 - 5 of 22

Similar Datasets

AfBPP of pyrrolopyrimidine α-helix mimetics

Project description:A wide range of small molecule scaffolds capable of mimicking protein α-helices to modulate protein-protein interactions have been reported, yet their target selectivity is poorly understood. Here, we report the affinity-based protein profiling of three structurally distinct classes of α-helix mimetics, N-substituted oligobenzamides, pyrrolopyrimidines, and oxopiperazines, all reported to inhibit the interaction between the tumour suppressor protein p53 and its negative regulator murine double minute 2 (MDM2).

2026-08-05 | PXD063432 | Pride

AfBPP of oxopiperazine α-helix mimetics

2026-08-05 | PXD063387 | Pride

AfBPP of N-substituted oligobenzamide α-helix mimetics

2026-08-05 | PXD063390 | Pride

AfBPP of α-helix mimetics in SJSA-1 cells

2026-08-05 | PXD063384 | Pride

Whole proteome time course experiment in SJSA-1 cells

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. In this experiment, we test the effect of Navtemadlin treatment on protein expression in SJSA-1 cells over the course of 24 h.

2025-04-28 | PXD058053 | Pride

Whole proteome experiment to validate treatment conditions in SJSA-1 cells

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. The selectivity of this molecule is poorly understood. So we synthesised and validated two photoactivatable clickable probes of Navtemadlin. This data shows the validation of treatment conditions through whole proteome proteomics experiments in order to ensure that the expression of key proteins such as MDM2 is uniform across conditions.

2025-04-28 | PXD058047 | Pride

Whole proteome experiment to validate treatment conditions in MCF-7 cells

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. The selectivity of this molecule is poorly understood. So we synthesised and validated two photoactivatable clickable probes of Navtemadlin. This data shows the validation of treatment conditions through whole proteome proteomics experiments in order to ensure that the expression of key proteins such as MDM2 is uniform across conditions.

2025-04-28 | PXD058050 | Pride

Comparison of SJSA-1 and MCF-7 whole proteome after Navtemadlin treatment

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. In this experiment, we compare the whole proteme of MCF-7 and SJSA-1 cells following Navtemadlin treatment in order to gain an insight into the cause of the observed differences in the off-target profile of this molecule in the two cell lines.

2025-04-28 | PXD058081 | Pride

Whole proteome time course experiment in MCF-7 cells

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. In this experiment, we test the effect of Navtemadlin treatment on protein expression in MCF-7 cells over the course of 24 h.

2025-04-28 | PXD058054 | Pride

AfBPP of Navtemadlin probes in SJSA-1 cells

Project description:Navtemadlin is a potent small moeclule inhibitor of the p53-MDM2 protein-protein interaction, that is being tested in Phase II/III clinical trials for the treatment of cancer. The selectivity of this molecule is poorly understood. So we synthesised and validated two photoactivatable clickable probes of Navtemadlin. This data shows the proteins enriched upon treatment of SJSA-1 cells with these probes.

2025-04-28 | PXD058033 | Pride